Charles Rhyee
Stock Analyst at TD Cowen
(1.99)
# 3,107
Out of 5,124 analysts
64
Total ratings
43.18%
Success rate
-7.66%
Average return
Main Sectors:
Stocks Rated by Charles Rhyee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GDRX GoodRx Holdings | Maintains: Buy | $7 → $6 | $2.71 | +121.40% | 8 | Nov 10, 2025 | |
| CRL Charles River Laboratories International | Maintains: Buy | $205 → $197 | $199.48 | -1.24% | 6 | Nov 10, 2025 | |
| COR Cencora | Maintains: Buy | $350 → $400 | $337.75 | +18.43% | 1 | Nov 10, 2025 | |
| CI The Cigna Group | Maintains: Buy | $387 → $333 | $275.23 | +20.99% | 1 | Nov 4, 2025 | |
| CVS CVS Health | Maintains: Buy | $99 → $100 | $79.36 | +26.01% | 1 | Nov 3, 2025 | |
| CAH Cardinal Health | Maintains: Buy | $183 → $225 | $205.50 | +9.49% | 3 | Nov 3, 2025 | |
| OPCH Option Care Health | Maintains: Hold | $30 → $27 | $31.86 | -15.25% | 2 | Nov 3, 2025 | |
| IQV IQVIA Holdings | Downgrades: Hold | $206 → $215 | $225.41 | -4.62% | 2 | Nov 3, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Hold | $183 → $172 | $182.22 | -5.61% | 5 | Oct 24, 2025 | |
| MEDP Medpace Holdings | Maintains: Sell | $356 → $462 | $561.65 | -17.74% | 6 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $297 → $380 | $223.23 | +70.23% | 4 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $830 → $864 | $820.29 | +5.33% | 4 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $23 → $25 | $17.25 | +44.93% | 3 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $9 → $8 | $7.00 | +14.29% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $3.63 | +37.74% | 2 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $100 → $50 | $4.91 | +918.33% | 3 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $56 | $16.19 | +245.89% | 2 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $360 → $280 | $11.38 | +2,360.46% | 3 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $4.00 | +1,150.00% | 2 | Jun 21, 2022 |
GoodRx Holdings
Nov 10, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.71
Upside: +121.40%
Charles River Laboratories International
Nov 10, 2025
Maintains: Buy
Price Target: $205 → $197
Current: $199.48
Upside: -1.24%
Cencora
Nov 10, 2025
Maintains: Buy
Price Target: $350 → $400
Current: $337.75
Upside: +18.43%
The Cigna Group
Nov 4, 2025
Maintains: Buy
Price Target: $387 → $333
Current: $275.23
Upside: +20.99%
CVS Health
Nov 3, 2025
Maintains: Buy
Price Target: $99 → $100
Current: $79.36
Upside: +26.01%
Cardinal Health
Nov 3, 2025
Maintains: Buy
Price Target: $183 → $225
Current: $205.50
Upside: +9.49%
Option Care Health
Nov 3, 2025
Maintains: Hold
Price Target: $30 → $27
Current: $31.86
Upside: -15.25%
IQVIA Holdings
Nov 3, 2025
Downgrades: Hold
Price Target: $206 → $215
Current: $225.41
Upside: -4.62%
ICON Public Limited Company
Oct 24, 2025
Maintains: Hold
Price Target: $183 → $172
Current: $182.22
Upside: -5.61%
Medpace Holdings
Oct 24, 2025
Maintains: Sell
Price Target: $356 → $462
Current: $561.65
Upside: -17.74%
Oct 7, 2025
Upgrades: Buy
Price Target: $297 → $380
Current: $223.23
Upside: +70.23%
Sep 24, 2025
Maintains: Buy
Price Target: $830 → $864
Current: $820.29
Upside: +5.33%
Nov 11, 2024
Maintains: Hold
Price Target: $23 → $25
Current: $17.25
Upside: +44.93%
Oct 31, 2024
Maintains: Hold
Price Target: $9 → $8
Current: $7.00
Upside: +14.29%
May 3, 2023
Maintains: Outperform
Price Target: $4 → $5
Current: $3.63
Upside: +37.74%
Mar 23, 2023
Downgrades: Market Perform
Price Target: $100 → $50
Current: $4.91
Upside: +918.33%
Oct 20, 2022
Maintains: Outperform
Price Target: $70 → $56
Current: $16.19
Upside: +245.89%
Aug 16, 2022
Maintains: Outperform
Price Target: $360 → $280
Current: $11.38
Upside: +2,360.46%
Jun 21, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $4.00
Upside: +1,150.00%